Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013

Diabetes Care

Volumn 40, Issue 4, 2017, Pages 468-475

  Lipska, Kasia J ^a   Yao, Xiaoxi ^b   Herrin, Jeph ^a   McCoy, Rozalina G ^b   Ross, Joseph S ^a,c   Steinman, Michael A ^d   Inzucchi, Silvio E ^a   Gill, Thomas M ^a   Krumholz, Harlan M ^a,c   Shah, Nilay D ^b,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TREND STUDY; ADOLESCENT; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG UTILIZATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 85019196764     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0985     Document Type: Conference Paper

References (44)

1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
2. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2014;37:985-992
3. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care 2015;38:1583-1591
4. Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW. Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care 2015;38:581-587
5. Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA 2014;311:2331-2333
6. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
7. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
8. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
9. American Diabetes Association. Standards of medical care in diabetesd2009. Diabetes Care 2009;32(Suppl. 1):S13-S61
10. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35: 2650-2664
11. American Diabetes Association. Summary of revisions. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2016;39(Suppl. 1): S4-S5
12. Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 2014; 174:1116-1124
13. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-1624
14. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014;174:678-686
15. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-2012
16. McCoy RG, Zhang Y, Herrin J, et al. Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010. Am J Manag Care 2015;21:e288-e296
17. Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
18. McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive treatment and severe hypoglycemia among adultswith type 2 diabetes. JAMA Intern Med 2016;176:969-978
19. Wallace PJ, Shah ND, Dennen T, Bleicher PA, CrownWH. Optum Labs: building a novel node in the learning health care system[published correction appears in Health Aff (Millwood) 2014;33: 1703]. Health Aff (Millwood) 2014;33:1187-1194
20. Optum Labs. Optum research data assets. Available from https://www.optum.com/content/dam/optum/resources/productSheets/5302-Data-Assets-Chart-Sheet-ISPOR.pdf. Accessed 15 September 2016
21. National Committee for Quality Assurance. HEDIS 2009 Volume 2 Technical Update [Internet]. National Committee for Quality Assurance. Available from http://www.ncqa.org/portals/0/\PolicyUpdates/HEDIS%20Technical%20Updates/09-CDC-Spec.pdf. Accessed 16 September 2016
22. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract 2010;89:189-195
23. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying personswith diabetes using Medicare claims data. Am J Med Qual 1999;14:270-277
24. Leong A, Dasgupta K, Bernatsky S, Lacaille D, Avina-Zubieta A, Rahme E. Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records. PLoS One 2013;8:e75256
25. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4
26. American Diabetes Association. Standards of Medical Care in Diabetesd2015. Diabetes Care 2015;38(Suppl. 1):S1-S93
27. Berkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med 2014;174:1955-1962
28. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668-2675
29. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function. Silver Spring, MD, U.S. Food and Drug Administration, 2016
30. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206
31. Zhang X, Bullard KM, Gregg EW, et al. Access to health care and control of ABCs of diabetes. Diabetes Care 2012;35:1566-1571
32. Berkowitz SA, Meigs JB, Wexler DJ. Age at type 2 diabetes onset and glycaemic control: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2010. Diabetologia 2013;56:2593-2600
33. Constantino MI, Molyneaux L, Limacher- Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013;36:3863-3869
34. Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care 2008;31:1985-1990
35. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
36. Lipska KJ, Montori VM. Glucose control in older adults with diabetes mellitus-more harm than good? JAMAInternMed 2013;173:1306-1307
37. Kirkman MS, Briscoe VJ, Clark N, et al.; Consensus Development Conference on Diabetes and Older Adults. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012;60: 2342-2356
38. Miller ME, Bonds DE, Gerstein HC, et al.; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of theACCORDstudy. BMJ 2010;340:b5444
39. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle Diabetes Study. J Clin Endocrinol Metab 2010;95:2240-2247
40. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract 2013;19:792-799
41. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35: 1897-1901
42. Bloomfield HE, Greer N, Newman D, et al. Predictors and Consequences of Severe Hypoglycemia in Adults With Diabetes - A Systematic Review of the Evidence. Washington, DC, U.S. Department of Veterans Affairs, 2012
43. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
44. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128